NCT00878722View on ClinicalTrials.gov

Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

May 31, 2009

Study Completion Date

April 30, 2012

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

PXD101

DRUG

idarubicin

Trial Locations (6)

34295

CHU Lapeyronie, Montpellier

35043

Uni Hospital Marburg, Marburg

66424

Uniklinik Homburg, Homburg

75475

Hôpital St. Louis, Paris

89081

Universitätsklinikum Ulm, Ulm

M20 4BX

Christie Hospital NHS Trust, Manchester

Sponsors
All Listed Sponsors
lead

Valerio Therapeutics

INDUSTRY